DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarterly / Interim Statement/9-month figures Eckert & Ziegler Q3/2016: Rise in Radiopharma segment income keeps the Group on track. Positive outlook for 2017. 03.11.2016 / 07:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, 3 November 2016. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist for isotope-based applications in medicine, science and industry headquartered in Berlin, achieved sales of EUR 103.1 million in the nine months from January to September 2016. The sales figures were almost exactly on par with the prior-year level of EUR 102.7 million. Currency effects and acquisitions did not play much of a role; the slight was largely based on organic growth. The sharpest rise in sales of EUR 3.0 million, or 12 %, to EUR 29.3 million was posted by the Radiopharma segment due to the continuing growth of pharmaceutical radioisotopes. The Isotope Products segment saw sales rise by EUR 1.2 million, or 2 %, to EUR 58.2 million. As expected, sales in the Radiation Therapy segment, on the other hand, declined by EUR 3.9 million, or 18 %, to EUR 17.8 million following the prior year's disposal of two divisions. Group earnings per share fell by EUR 0.27, or 19 %, year on year to EUR 1.43. This amount is slightly higher than planned; as a result, the Executive Board is confident that earnings per share for the full year will amount to EUR 1.80 as forecast. Eliminating the losses for 2016 that arose from the winding-down of a Californian subsidiary, earnings per share amounted to EUR 1.47, that is to say EUR 0.04 more per share. The scheduled decline in profits by nearly 20% was due to the EUR 6.4 million drop in extraordinary income which stood at a record figure of EUR 8.8 million in the prior year as a result of, among other things, the sale of an investment (OctreoPharm Sciences). Excluding extraordinary effects and the financial result for both periods, and including the discontinued operations, there has been a significant improvement in the results of operations. While sales remained more or less unchanged, the Group's gross margin rose by EUR 2.1 million and administrative and selling expenses fell by EUR 3.0 million. The disposals of loss-bringer operations and the closure of unprofitable subsidiaries enabled the Group to reduce its cost base by a total of EUR 5.4 million, or 5 % of sales, within a period of twelve months. In 2017 earnings are expected to grow and could exceed EUR 2.00 per share, assuming that exchange rates remain stable and excluding acquisitions and the sale of divisions. Sales of just under EUR 150 million are expected. The complete quarterly financial statements can be viewed under: http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/ englisch/euz316e.pdf About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 660 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de --------------------------------------------------------------------------- 03.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 516733 03.11.2016